Q3 2025 Management View John Jacobs, President, CEO & Director, stated that Novavax has made significant progress in Q3 by ...
Stocktwits on MSN
Novavax Stock Faces Retail Backlash As Shah Capital Warns Of Proxy Fight And Presses For A Sale
Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...
Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.
Novavax's vaccine targets the highly contagious omicron subvariant JN.1, which began circulating widely in the U.S. earlier this year. JN.1 only accounted for 0.2% of cases circulating nationwide as ...
Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Gaithersburg company ...
13d
Novavax Inc (NVAX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Challenges
Novavax Inc (NVAX) focuses on innovation and partnerships amid financial hurdles, aiming for profitability by 2028.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback